News

BERKELEY HEIGHTS, N.J. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three

- Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib - - Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow - - Cash Runway to Early 2023 - - Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Aug.

Cyclacel will also participate in the BTIG Virtual Biotechnology Conference BERKELEY HEIGHTS, N.J. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on

-Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated Across Multiple Solid Tumor and Lymphoma Types in Streamlined Registration-Directed Study- BERKELEY HEIGHTS, N.J. , July 13, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the

BERKELEY HEIGHTS, N.J. , July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Ladenburg

- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -  - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -  - Following Recent Financing, Cash Runway Extended to Early 2023 -  - Conference Call Scheduled May 12, 2021 at

BERKELEY HEIGHTS, N.J. , May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results and provide a

BERKELEY HEIGHTS, N.J. , March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced

BERKELEY HEIGHTS, N.J. , March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the

BERKELEY HEIGHTS, N.J. , March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public

BERKELEY HEIGHTS, N.J. , March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer shares of its

Conference Call Scheduled February 25, 2021 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology,

BERKELEY HEIGHTS, N.J. , Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial

BERKELEY HEIGHTS, N.J. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021

– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum , M.D. as Chief Medical Officer – –   $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures – BERKELEY HEIGHTS, N.J. , Jan.

BERKELEY HEIGHTS, N.J. , Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech

- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY HEIGHTS, N.J. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.

Former CMO & Head of R&D of ArQule joins the Board BERKELEY HEIGHTS, N.J. , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today

- Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell

BERKELEY HEIGHTS, N.J. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results